GreenLight SPAC Presentation Deck

GreenLight Bio. & Environmental Impact - Shared mission to deliver global Impact GreenLight Biosciences Andrey J. Zarur, Ph.D CEO Susan Keefe, MBA CFO Environmental Impact Acquisition Corp. Dan Coyne CEO & President Marc Marano CFO Key Highlights GreenLight Biosciences ("GreenLight" or the "Company") is a mission-driven synthetic biology platform developing RNA-based solutions for agriculture (plant health & pest control) and healthcare (vaccines & therapeutics) and various applications in these large segments ● ● ● GreenLight and Environmental Impact Acquisition Corp. ("ENVI") are combining to build out the Company's RNA production capabilities and advance its pipeline of 14 agriculture and human health products Existing GreenLight shareholders will roll 100% of their equity; several have also invested in PIPE ENVI has $207 million of cash in trust and a PIPE of $105 million Pro forma enterprise value of $1.2 billion for GreenLight ● GreenLight is targeting two of humanity's biggest challenges and largest economic opportunities: Food Security / Scarcity and Human Health ● GreenLight's platform is enabled by a proprietary, cell-free manufacturing process that produces high- quality RNA solutions in a more scalable, flexible and affordable manner than alternative technologies ENVI is excited to be GreenLight's aligned partner in its mission to address urgent food security needs and enable a healthier and "pandemic proof" future for humanity Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 6

View entire presentation